What we want
- All women with non-mucinous ovarian cancer to be BRCA1/2 tested at diagnosis
What we've done
- In March 2014 we launched our BRCA1/2 Gene Testing Policy Report in Parliament
- For Ovarian Cancer Awareness Month 2014 we launched our BRCA Risk Tool - helping women to explore whether their family history puts them at risk of developing ovarian cancer
- Our report cals for all women in England, Wales and Northern Ireland diagnosed with non-mucinous epithelial ovarian cancer to be tested for the BRCA1/2 gene mutation as is already the case in Scotland
- In October 2014 we released a report calling for all women diagnosed with ovarian cancer to have the same uniform access to BRCA testing no matter where they live in the UK.
- In November 2014 we balloted for a Westminster Hall debate about BRCA and ovarian cancer. Hosted by Margaret Ritchie MP, she told the government: "It is clear that we need to implement a system across the UK and Northern Ireland where women diagnosed with ovarian cancer automatically receive a BRCA gene test and have the option for close relatives to take that test as well."
- Women with ovarian cancer have a 15-20% chance of carrying a BRCA gene mutation
- Inheriting a faulty gene known as the BRCA1 or BRCA2 mutation creates a greater chance, 35-60%, of developing ovarian cancer
- The Ovarian Cancer Action BRCA1/2 Gene Testing Policy Report states that trials at The Royal Marsden have demonstrated that testing can be carried out in a way that is affordable, deliverable and beneficial to women with the disease and their families
- Knowing that you carry a BRCA gene mutation can help inform women's treatment paths and may provide trials for them to participa
- Women who know that they carry BRCA gene mutations can also inform their families and potentially prevent future cancers or help to spot them early
- Currently in order to qualify for BRCA1/2 testing, NICE recommends a likelihood of having inherited the genetic mutation of 10% or over, determined through looking at family history. But studies have indicated that around 50% of women diagnosed with non-mucinous epithelial ovarian cancer have no family history of the disease